FFAR1 and type 2 diabetes mellitus: As a major mechanism to induce incretin secretion in the gut, GPR40 agonists have many potential efficacies, including suppression of appetite and inducing weight loss, controlling hyperglycemia in T2D, resolving liver steatosis and inflammation, etc. (reviewed in Gimeno et al., 2020 and Secor et al., 2021).